PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Fuchs, A.* ; Gliwinski, M.* ; Grageda, N.* ; Spiering, R.* ; Abbas, A.K.* ; Appel, S.* ; Bacchetta, R.* ; Battaglia, M.* ; Berglund, D.* ; Blazar, B.* ; Bluestone, J.A.* ; Bornhaeuser, M.* ; ten Brinke, A.* ; Brusko, T.M.* ; Cools, N.* ; Cuturi, M.C.* ; Geissler, E.* ; Giannoukakis, N.* ; Golab, K.* ; Hafler, D.A.* ; van Ham, S.M.* ; Hester, J.* ; Hippen, K.* ; Di Ianni, M.* ; Ilic, N.* ; Isaacs, J.* ; Issa, F.* ; Iwaszkiewicz-Grzes, D.* ; Jaeckel, E.* ; Joosten, I.* ; Klatzmann, D.* ; Koenen, H.* ; Van Kooten, C.* ; Korsgren, O.* ; Kretschmer, K. ; Levings, M.* ; Marek-Trzonkowska, N.M.* ; Martínez-Llordella, M.* ; Miljkovic, D.* ; Mills, K.H.G.* ; Miranda, J.P.* ; Piccirillo, C.A.* ; Putnam, A.L.* ; Ritter, T.* ; Roncarolo, M.G.* ; Sakaguchi, S.* ; Sanchez-Ramon, S.* ; Sawitzki, B.* ; Sofronic-Milosavljevic, L.* ; Sykes, M.* ; Tang, Q.* ; Vives-Pi, M.* ; Waldmann, H.* ; Witkowski, P.* ; Wood, K.J.* ; Gregori, S.* ; Hilkens, C.M.U.* ; Lombardi, G.* ; Lord, P.* ; Martinez-Caceres, E.M.* ; Trzonkowski, P.*

Minimum information about T regulatory cells: A step toward reproducibility and standardization.

Front. Immunol. 8:1844 (2018)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.511
1.484
31
39
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Minimum Information Model ; T Regulatory Cells ; Immunotherapy ; Good Manufacturing Practice ; Cell Therapy ; Immune Tolerance; Chimeric Antigen Receptor; Versus-host-disease; Adoptive Transfer; In-vitro; Transplantation; Blood; Expansion; Allograft; Tolerance; Therapies
Language english
Publication Year 2018
HGF-reported in Year 2018
ISSN (print) / ISBN 1664-3224
e-ISSN 1664-3224
Journal Frontiers in Immunology
Quellenangaben Volume: 8, Issue: , Pages: , Article Number: 1844 Supplement: ,
Publisher Frontiers
Publishing Place Lausanne
Reviewing status Peer reviewed
Institute(s) Institute of Pancreatic Islet Research (IPI)
POF-Topic(s) 90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502600-009
DOI 10.3389/fimmu.2017.01844
WOS ID WOS:000419897500001
Scopus ID 85040816793
PubMed ID 29379498
Erfassungsdatum 2018-03-01
[➜Report correction]